| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 The Integrated Cancer Prevention Center and 2 Lung and Allergy Institute, Tel Aviv Medical Center; 3 The David and Inez Myers Laboratory for Genetic Research; 4 Department of Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv, Israel; 5 Tumor Immunology Programme, D010, German Cancer Research Center, Heidelberg, Germany; and 6 Columbia University, New York, New York
Requests for reprints: Nadir Arber, Integrated Cancer Prevention Center, Tel Aviv Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel. Phone: 972-3-697-4968; Fax: 972-3-695-0339; E-mail: narber{at}post.tau.ac.il.
Key Words: CD24 monoclonal antibodies siRNA microarray chemotherapy
CD24 is a potential oncogene reported to be overexpressed in a large variety of human malignancies. We have shown that CD24 is overexpressed in 90% of colorectal tumors at a fairly early stage in the multistep process of carcinogenesis. Anti-CD24 monoclonal antibodies (mAb) induce a significant growth inhibition in colorectal and pancreatic cancer cell lines that express the protein. This study is designed to investigate further the effects of CD24 down-regulation using mAb or small interfering RNA in vitro and in vivo. Western blot analysis showed that anti-CD24 mAb induced CD24 protein down-regulation through lysosomal degradation. mAb augmented growth inhibition in combination with five classic chemotherapies. Xenograft models in vivo showed that tumor growth was significantly reduced in mAb-treated mice. Similarly, stable growth inhibition of cancer cell lines was achieved by down-regulation of CD24 expression using short hairpin RNA (shRNA). The produced clones proliferated more slowly, reached lower saturation densities, and showed impaired motility. Most importantly, down-regulation of CD24 retarded tumorigenicity of human cancer cell lines in nude mice. Microarray analysis revealed a similar pattern of gene expression alterations when cells were subjected to anti-CD24 mAb or shRNA. Genes in the Ras pathway, mitogen-activated protein kinase, or BCL-2 family and others of oncogenic association were frequently down-regulated. As a putative new oncogene that is overexpressed in gastrointestinal malignancies early in the carcinogenesis process, CD24 is a potential target for early intervention in the prevention and treatment of cancer. [Cancer Res 2008;68(8):2803–12]
This article has been cited by other articles:
![]() |
C. Y. Chen, H. Kimura, M. A. Landek-Salgado, J. Hagedorn, M. Kimura, K. Suzuki, W. Westra, N. R. Rose, and P. Caturegli Regenerative Potentials of the Murine Thyroid in Experimental Autoimmune Thyroiditis: Role of CD24 Endocrinology, January 1, 2009; 150(1): 492 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rappa, O. Fodstad, and A. Lorico The Stem Cell-Associated Antigen CD133 (Prominin-1) Is a Molecular Therapeutic Target for Metastatic Melanoma Stem Cells, December 1, 2008; 26(12): 3008 - 3017. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |